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Abstract
Background: HDGF is a growth factor which is overexpressed in a wide range of tumors. Importantly, expression
levels were identified as a prognostic marker in some types of cancer such as melanoma.
Methods: To investigate the presumed oncogenic/transforming capacity of HDGF, we generated transgenic mice
overexpressing HDGF in melanocytes. These mice were bred with mice heterozygous for a defective copy of the
Ink4a tumor suppressor gene and were exposed to UV light to increase the risk for tumor development both
genetically and physiochemically. Mice were analyzed by immunohistochemistry and Western blotting.
Furthermore, primary melanocytes were isolated from different strains created.
Results: Transgenic animals overexpressed HDGF in hair follicle melanocytes. Interestingly, primary melanocytes
isolated from transgenic animals were not able to differentiate in vitro whereas cells isolated from wild type and
HDGF-deficient animals were. Although, HDGF
-/-/Ink4a
+/- mice displayed an increased number of epidermoid cysts
after exposure to UV light, no melanomas or premelanocytic alterations could be detected in this mouse model.
Conclusions: The results therefore provide no evidence that HDGF has a transforming capacity in tumor
development. Our results in combination with previous findings point to a possible role in cell differentiation and
suggest that HDGF promotes tumor progression after secondary upregulation and may represent another protein
fitting into the concept of non-oncogene addiction of tumor tissue.
Background
HDGF is a heparin-binding growth factor originally iso-
lated from conditioned medium of HuH-7 cells [1,2].
Several studies reported that HDGF promotes prolifera-
tion, differentiation, and migration of several cell types,
such as vascular smooth muscle cells, when applied exo-
geneously to the culture medium or when overexpressed
endogeneously [3-6]. Studies revealed that HDGF is
expressed in most organs (liver, brain, lung, intestine
etc.) both during embryonic development and through-
out the organism’s life [7]. Together with its mitogenic
activity HDGF was therefore implicated in organ devel-
opment and tissue differentiation [5,8,9]. Models of
vascular injury and ulcerative colitis pointed towards a
function of HDGF in tissue repair [10-12]. This sugges-
tion was supported by the classification of HDGF as an
alarmin, a protein signaling cell and tissue damage to
the immune system [13,14]. Surprisingly, HDGF-knock-
out (HDGF
-/-) mice are viable and show no develop-
mental phenotype [15]. Over the last years, the
overexpression of HDGF in various tumors attracted
more and more attention. Up to now HDGF has been
reported to be overexpressed in non-small cellular lung
cancer [16], hepatocellular carcinoma [17,18], colorectal
carcinoma [19,20], oesophagal carcinoma [21], pancrea-
tic carcinoma [22] and melanoma [23]. Furthermore, a
correlation between the degree of HDGF overexpression
and the course of disease was found for some types of
cancer, including melanoma, leading to the classification
of HDGF as a novel prognostic marker [16,18,20-22,24].
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in tumor angiogenesis [25,26], metastasis [19,26], and
apoptosis [27,28]. So far, the influence of HDGF on
tumors was studied by si-RNA mediated or antibody-
mediated reduction of HDGF in tumor mouse models.
The accordant results showed, that a reduction of
HDGF in tumor cells resulted in the formation of smal-
ler tumors, reduced tumor angiogenic and metastatic
capacity, and an improved response to chemotherapeu-
tic treatment [25,26]. However, a direct influence of an
initial overexpression of HDGF has so far not been
investigated.
In this study, we present for the first time results on
the presumed putative oncogenic/transforming capacity
of this mitogenic growth factor by studying the influ-
ence of HDGF on tumor development in a transgenic
mouse model overexpressing HDGF in melanocytes, a
cell type from which malignant melanoma, a highly
aggressive type of cancer, arises. This model was gener-
ated to study the influence of HDGF-overexpression in
a non-transformed cell type in vivo.
Methods
Construction of the Tyrosinase(Tyr)-HDGFgene construct
The Tyr-HDGFgene construct consists of the complete
HDGF genomic sequence, except for intronI which was
shortened from 6, 377 bp to 786 bp. The shortened
HDGF gene was cloned into the phs3.6 Tyrosinase-lacZ
(-6.1) vector (kindly provided by Friedrich Beermann,
IRES, Epalinges, Switzerland) in multiple steps. First, the
lacZ gene was removed by incubating the vector with
the restriction enzymes SmaI and NotI (Fermentas, St.
Leon-Rot, Germany). Before the plasmid was allowed to
religate, the ends were blunted by using the Klenow
Fragment (Fermentas, St. Leon-Rot, Germany). In a sec-
ond step, this plasmid was linearized through incubation
with XhoI and ligated with the compatible ends of the
SalI incubated shortened HDGF gene.
Generation of Transgenic Mice
The HDGF
Tyr-transgenic mice were generated through
injection of the Tyr-HDGFgene construct into the pro-
nucleus of fertilized eggs. The genotype of the emanated
mice and their offspring was determined by PCR on
DNA from tail biopsies. The following primers were
used to distinguish the Tyr-HDGFgene construct from
the wildtype HDGF gene: mHDGFgeneConstruct_sense,
5’-GTATCGATAAGCTTGGTACCATG-3’ and
HDGFwt-antisense, 5’-CTTGGTATTTGTTGGC
TGTTGA-3’. PCR conditions were as follows: denatura-
t i o nf o r3m i na t9 5 ° C ,f o l l o w e db y3 5c y c l e so f3 0s e c
at 95°C, 60 sec at 54°C and 60 sec at 72°C. This reaction
resulted only in a fragment of 943 bp if the Tyr-
HDGFgene construct was present in the sample DNA.
All mice were backcrossed for more than ten genera-
tions into the C57BL6N background. Furthermore, the
following mouse lines were generated by backcrossing:
HDGF
Tyr/HDGF
-/-,H D G F
Tyr/Ink4a
-/-, HDGF
-/-/Ink4a
-/-.
The HDGF
-/- m o u s el i n ew a sg e n e r a t e db yR a i n e rG a l -
litzendörfer (IBMB, University of Bonn, Germany) [15],
whereas the Ink4a
-/- mice were kindly provided by
Clemens Schmitt (Charité - University Berlin, Germany)
with permission of Manuel Serrano (Spanish National
Cancer Research Centre, Madrid, Spain) [29].
Mice used in this study were housed under standard
conditions in a 12 hour light-dark cycle and provided
with food and water ad libitum. All experiments were
carried out in accordance with local and state regula-
tions for animal research.
Southern Blot Analysis
Genomic DNA was isolated from mouse tails by phenol/
chloroform extraction. 10 μgD N Aw a sf r a g m e n t e db y
incubation with the restriction enzymes BglII and Hin-
dIII (Fermentas, St. Leon-Rot, Germany), separated on a
0.8% agarose gel and blotted onto a Hybond™-N
+ nylon
filter (Amersham, GE Healthcare, Munich, Germany) by
performing a capillary blot. The probe spanning exonIV,
intronIV and exonV of the HDGF gene was labeled with
[a
32P ] - d C T Pb yu s i n gt h eM e g a p r i m e - D N Al a b e l i n g
Kit
® (Amersham, GE Healthcare, Munich, Germany)
according to manufacturer’s instruction. Hybridization
was carried out by incubating the membrane in FBI-buf-
fer (SSPE buffer, 10% PEG-8000, 7% SDS) containing
the radioactive labeled probe (1 × 10
6 cpm per cm
2 fil-
ter). Signals were detected by exposing the filters to
films (Kodak, Stuttgart, Germany) for 24 hours.
UVB-Irradiation of newborn mice
Mice of 1-3 days of age were placed on a sterile cotton
sheet and irradiated with a single UVB-dose of 6.14 kJ/
m
2. The light pannel contained four TL/12 UVB-light
bulbs. The dose was determinded by a scanning spectro-
photometer. The following genotypes were used for this
experiment: HDGF
Tyr/INK4a
+/-,I n k 4 a
+/-,H D G F
-/-/
INK4a
+/-, HDGF
Tyr, wildtype and HDGF
-/-.
Isolation of total RNA and RT-PCR
Total RNA was isolated using Trizol (Invitrogen), fol-
lowing the manufacturer’s instructions. cDNA was
synthesized from 1 μg total RNA using QuantiTect
Reverse Transcription Kit (Qiagen) according to the
manual. For the detection of HDGF-cDNA a PCR with
primer HDGF-sense (5’GCGGCGGTACCATGTCGC-
GATCCAACCGG3’)a n dH D G F - a n t i s e n s e( 5 ’
GAGACTCGAGT GAGTGAGGGAGTAG3’), and RED-
Taq
® ReadyMix
™ PCR Reaction Mix (Sigma) was per-
formed following the manufacturer’s instructions. To
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the Tyr-HDGFgene construct the primers mHDGFgene-
Construct_sense (5’GTATCGATAAGCTTGGTAC-
CATG3’)a n dH D G F - a n t i s e n s e
(5’GAGACTCGAGTGAGTGAGGGAGTAG3’)w e r e
used. PCR conditions were as follows: denaturation for
3 min at 95°C, followed by 35 cycles of 30 sec at 95°C,
60 sec at 56°C and 60 sec at 72°C.
Immunostaining and Histology
Tissue sections were prepared from skin samples from
each group of mice and for each treatment. Tissues
were fixed at 4°C over night (4% buffered formalin/10%
sucrose), paraffin embedded and cut into 4 μm sections.
HE staining was performed as previously described [30].
Sections were deparaffinized in 10 mM Citrate-buffer,
pH 6.0 and blocked with 3% BSA/TBS. Affinity-purified
polyclonal rabbit-anti-mouse HDGF (dilution 1:100 in
1% BSA/TBS) antibodies (Abouzied et al., 2004) were
used to stain mouse tissue. Control slides were incu-
bated with 1% NGS/TBS (normal goat serum (Abcam)
in TBS) without primary antibody. For immunofluores-
cent detection of HDGF, goat-anti-rabbit-Cy3 was used
as a secondary antibody. Nuclei were stained with DAPI
(Sigma). Images were aquired on an Axioskop 2 MOT
(Carl Zeiss, Jena, Germany) microscope equipped with
an Olympus XL-50 (Olympus, Hamburg, Germany) digi-
tal camera.
Bleaching of pigmented Tissue sections
Bleaching of tissue sections was carried out after depar-
affinization in a solution consisting of 55% benzyl alco-
hol, 25% acetone, 15% H2O2 (10%) and 5% ammonium
hydroxide solution (25%). According to the grade of pig-
mentation incubation time ranged from 15-120 min at
37°C.
In Situ Hybridisation
For the detection of tyrosinase mRNA a tyrosinase sense
(Tyr_s - control) and antisense (Tyr_as - experimental)
probe were generated from C57BL6 skin cDNA (Primer:
Tyr_sense 5’-AGTCTGCAG TACTCGAGTGTTTTG-
TATTGCCTTCTGTGGA-3’;T y r _ a n t i s e n s e5 ’-
TGAAGCTTACCCATT GTTCATTTGGCCAT-3’)a n d
transcribed on a T7-based plasmid using a digoxigenin
(DIG) RNA-labeling kit (Roche Applied Science, Man-
heim, Germany) according to the manufacturer’sm a n -
ual. Four micrometer sections were cut from paraffine
embedded skin samples and adhered to glass slides
(Superfrost Ultra Plus, Thermo Fisher Scientific, Walt-
man, MA). In situ hybridization was performed as pre-
viously described by Fewou and coworkers [31]. Briefly,
after rehydration, sections were post-fixed in 4% paraf-
ormaldehyde/PBS, before endogenous peroxidases were
inhibited by incubation with 1% H2O2/PBS for 15 min.
Thereafter, sections were treated with proteinase K (10
μg/ml; 4 min) and permeabilized with 0.25% Triton X-
100 (4 min). Afterwards, the slices were incubated with
0.2 M HCl (8 min), 0.1 M triethanolamine/2.5 μl/ml
acetic anhydride (10 min), and washed for 10 min with
2 × SSC (0.15 M NaCl/0.015 M sodium citrate) at 50°C.
DIG-labeled probes (diluted 1:1, 000 in 50% (v/v) forma-
mide, 1% Denhardt’s solution, 0.2% SDS, and 10% (w/v)
hybridization salt (3 M NaCl, 0.1 M PIPES and 0.1 M
EDTA)) were allowed to hybridize to tissue-mRNA over
night at 70°C. After removal of the hybridization solu-
tion, sections were washed with 2 × SSC at 60°C, for 20
min with 50% formamide/1 × SSC at 60°C and for 45
min with 0.1 × SSC at 70°C. DIG-labeled probes were
detected by incubation with alkaline phosphatase-conju-
gated anti-DIG Fab fragment (Roche Applied Science,
Manheim, Germany). Bound antibodies were further
visualized by incubating the slides with BMPurple™
(Roche Applied Science, Manheim, Germany) for 7-10
days. Color development was stopped by washing with
ddH2O, before embedding the slides with Mowiol.
Images were aquired on an Axioskop 2 MOT (Carl
Zeiss, Jena, Germany) microscope equipped with an
Olympus XL-50 (Olympus, Hamburg, Germany) digital
camera.
Primary Melanocyte Culture
1-3 day old mice were used for the isolation of melano-
cytes. Neonatal mice were decapitated and desinfected,
before the abdominal skin was drawn off. The whole
skin was incubated overnight in dispase II-solution (5
mg/ml; 4°C; slightly shaking) before the epidermis could
be separated from the dermis. Dissociation of the epi-
dermal cells was achieved by incubation of the epider-
mis floating on 1 ml trypsin solution (0.025% trypsin/
0.02% EDTA/PBS; 5 min; room temperature) with the
stratum corneum facing up. The reaction was stopped
by adding 3 ml of FCS containing medium and the epi-
dermal cells could subsequently be detached by gentle
scraping with a spattle. The cell suspension was sedi-
mented by centrifugation (600 × g; 5 min; room tem-
perature), before the cells were resuspended in fresh
melanocyte medium (RPMI Gibco BRL including 5%
FCS (Invitrogen), 2 mM Glutamax™ (Gibco BRL), 100
IU penicillin (Gibco BRL), 100 μg streptomycin (Gibco
BRL), 4 μg/ml insulin (Sigma), 100 U/ml catalase
(Sigma), 10 μg/ml BPE (Sigma)) and seeded into a 10
cm cell culture dish. After four days the keratinocytes
made up a confluent cell layer on which the melano-
cytes grew. The melanocytes were detached from the
keratinocytes by trypsinization for 1 min. The cells were
sedimented and resuspended in melanocyte medium
supplemented with 23 ng/ml 3-isobutyl-1-
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phorbol-13-acetate (TPA). Medium was replaced every
three days.
Western Blot Analysis
Tissue samples and cell pellets were lysed in HEPES buf-
fer (20 mM HEPES/OH pH 7.4, 250 mM sucrose, 10
mM KCl, 1.5 mM MgCl2,1m ME D T A ,1m ME G T A ,1
mM PMSF, 1 mM DTT, 50 μg/ml DNaseI, 0.1% SDS (v/
v), 1 μg/ml leupeptin, 1 μg/ml pepstatin). The lysates
were incubated on ice for 20 minutes followed by centri-
fugation at 18, 000 × g and 4°C for 20 min. The protein
concentration of the supernatant was determined by
using the Bio-Rad DC protein assay system (Bio-Rad
Laboratories, Munich, Germany) according to the manu-
facturer’s instructions. Soluble homogenates (40 μgt o t a l
protein) were separated under denaturating conditions in
10% sodium dodecyl sulfate-polyacrylamide gels by elec-
trophoresis and transferred onto pvdf-membranes
(BioRad, Munich, Germany) using semidry blotting [32].
Membranes were stained with Coomassie solution (Coo-
massie Brilliant Blue R, Serva 35051) to assess equal load-
ing and destained (Destaining solution: 5% methanol, 7%
acetic acid in H2O) afterwards. Thereafter, membranes
were blocked with 5% skim milk/TBS, followed by incu-
bation with affinity-purified polyclonal rabbit-anti-mouse
HDGF antibody solution (dilution 1:1, 000) [7]. Subse-
quently, membranes were incubated with a goat-anti-rab-
bit IgG conjugated to horseradish peroxidase (dilution
1:10, 000) (Dianova, Hamburg, Germany). Immunoreac-
tive proteins were visualized with enhanced chemilumi-
nescence (Pierce ECL Western Blotting Substrate, Pierce,
R o c k f o r d ,I L )a n de x p o s u r et of i l m s( K o d a k ,S t u t t g a r t ,
Germany) according to manufacturer’s instruction.
Statistical Analysis
Statistical analysis of the epidermoid cysts was carried
out by applying a chi-square contingency table test.
Results
Generation and genotyping of transgenic mice (HDGF
Tyr)
To investigate whether HDGF exhibits oncogenic/trans-
forming capacities and whether the observed HDGF-
overexpression in various types of tumors promotes
tumor development and/or progression, a mouse model
was generated overexpressing HDGF only in melano-
cytes. To allow the expression of possible alternative
splicing products we constructed a transgene containing
all exons and introns of the murine HDGF gene with a
shortened intronI (HDGFgene; Figure 1A). To test the
integrity of the protein expressed from this construct it
was first cloned under the control of a CMV promoter
and expressed in HEK cells. Western blot analysis of
cell lysates confirmed the expression of two protein
variants at molecular weights resembling HDGF protein
variants (Additional file 1A) as can be observed in sev-
eral tissues [7]. To target the expression to pigment
cells, the HDGFgene construct was further cloned under
the control of the tyrosinase promoter/enhancer element
driving the expression of the melanocyte-specific protein
tyrosinase (Figure 1A). Linearized and purified plasmid-
DNA was used for pronuclear injection. Out of 61 off-
spring, 15 were initially genotyped positive for the inte-
gration of the Tyr-HDGFgene construct by PCR-
genotyping. Figure 1B shows exemplarily the PCR result
for the offspring 7159 and 889. In case of an integration
of the Tyr-HDGFgene construct, a 943 bp fragment was
amplified, which was absent in the wildtype-DNA con-
trol. The integration was confirmed by performing a
Southern blot (Figure 1C). Due to fragmentation of the
genomic DNA with the restriction enzymes BglII and
HindIII, two DNA-fragments could be detected with the
help of the radioactivly labeled probe encompassing exo-
nIV, intronIV and exonV. The 4, 386 bp fragment,
representing the wildtype allele, could be detected in all
samples, whereas the 2, 570 bp fragment representing
the Tyr-HDGFgene construct was only detected in the
samples of the offspring 7159 and 889 but not in the
samples of offspring 7165 and the wildtype control. Off-
spring 7159 and 889 were used as founders for two
independent transgenic mouse lines.
Analysis of HDGF
Tyr mice
Tyrosinase-HDGF (HDGF
Tyr)t r a n s g e n i cm i c ew e r e
viable, fertile, and neither showed defects in pigmenta-
tion nor did they prematurely turn gray. HDGF expres-
sion in skin samples of HDGF
Tyr mice was first
compared to that of wildtype mice by immunfluores-
cence (Figure 2A a, b, f, g). Staining of wildtype hair fol-
licles revealed a nuclear HDGF expression in cells of the
hair follicle including the pigmented region (Figure 2A
a, f). However, in HDGF
Tyr mice a bright signal for
HDGF was obtained in the pigmented area of the hair
follicles (Figure 2A b, g). To ensure that the detected
protein represents transgenic HDGF, HDGF
Tyr mice
were backcrossed into the HDGF
-/- mouse line. Indeed,
immunfluorescent staining of skin samples from
HDGF
Tyr/HDGF
-/- ( F i g u r e2 Ac ,d ,h ,i )i nc o m p a r i s o n
to HDGF
-/- (Figure 2A e, j) mice proofed that the dis-
tinct staining pattern seen in HDGF
Tyr mice originates
from the transcript of the Tyr-HDGFgene construct. In
situ hybridization using a tyrosinase RNA probe demon-
strates that the observed HDGF-staining pattern corre-
lates with the localization of melanocytes in the
pigmented area of the hair follicles (Additional file 2).
To further investigate the expression of the Tyr-
HDGFgene construct, RT-PCRs were performed on
cDNA from brain, eye, skin samples (Additional file
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(red arrows) showing strongest expression in the brain.
This observation corresponds to an already known leaki-
ness of the tyrosinase promoter in brain tissue [33-36].
Comparison of DNA sequences from the skin PCR-pro-
duct of wildtype HDGF to transgenic HDGF revealed no
mutations over the whole length of the transcript (data
not shown). Western blot analysis of skin samples did
not reveal significant differences between wildtype and
transgenic animals (data not shown) most likely because
melanocytes account for only 5-10% of mouse skin cells.
Because the RT-PCR results confirmed the previously
published leakiness of the Tyrosinase promoter/enhan-
cer construct in the brain, a western blot analysis of
brain lysates was performed (Additional file 1B). The
result showed that in the brain of HDGF
Tyr/HDGF
-/-
mice a HDGF protein could be detected migrating at
the same height as HDGF from wildtype tissue (white
arrow). To further investigate HDGF expression in mel-
anocytes, primary melanocytes were isolated from neo-
natal skin of HDGF
Tyr, wildtype and HDGF
-/- mice to
quantify the elevated HDGF-expression in HDGF
Tyr
melanocytes by immunofluorescent stainings. Wildtype
and HDGF
-/- melanocytes grew in cell culture and dif-
ferentiated into pigment producing melanocytes while
forming a near confluent cell layer (Figure 2B b, c, e, f).
Surprisingly, very few pigmented cells could be obtained
from HDGF
Tyr mice (arrows in Figure 2B a, d). How-
ever, Western blot analysis of primary melanocyte
lysates revealed that wildtype melanocytes express no
substantial amount of HDGF (Figure 2C), whereas
HDGF could be detected in B16F10 mouse melanoma
cell lysate. In addition HDGF could also not be detected
in lysates from HDGF
Tyr melanocyte cultures.
In summary, the strong HDGF signal in hair follicle
melanocytes from HDGF
Tyr and HDGF
Tyr/HDGF
-/-
mice compared to wildtype and HDGF
-/- ones, respec-
tively as well as the overlapping HDGF-protein and tyr-
osinase-mRNA expression pattern confirmed that the
generation of the HDGF
Tyr transgenic mice resulted in
an elevated HDGF-expression in hair follicle melano-
cytes. HDGF
Tyr and wildtype mice were monitored over
24 month, but no effect of the additional HDGF could
be observed in vivo. In particular, no melanocytic lesions
or melanoma could be detected in HDGF
Tyr mice.
Analysis of HDGF
Tyr mice under tumor growth promoting
conditions
To uncover the putative oncogenic/transforming capa-
city of HDGF, HDGF
Tyr and HDGF
-/- mice were
Figure 1 Generation of HDGF
Tyr transgenic mice. A: Schematic map of the Tyrosinase-HDGFgene construct. The Tyrosinase Promotor/
Enhancer element is located approximately 6.1 kb in front of exonI. The HDGF gene consists of the complete exon/intron structure, except
intronI was shortened from 6, 377 bp to 786 bp. The construct was separated from the vector backbone by incubation with the restriction
enzyme BssHII, purified, and injected into the pronucleus of fertilized mouse egg cells. Boxes 1-6 indicate exons (white parts represent non-
coding, black parts indicate coding regions). Arrows show the site of primer annealing for PCR-genotyping. The probe used for Southern blot
analysis spans exonIV, intronIV and exonV. B: Examples of a polymerase chain reaction (PCR) genotyping of mouse tail DNA. Primers a and b
were used to amplify the 943 bp fragment. Wildtype DNA was used as a negative control. 10 ng of Tyr-HDGFgene construct plasmid DNA was
used as a positive control. C: Exemplary illustration of a Southern blot analysis of mouse tail DNA from the PCR-positive offspring 7159 and 889
and the PCR-negative offspring 7165 and wildtype mouse tail DNA as a control. The radioactively labeled probe spanning exonIV, intronIV and
exonV hybridizes to both fragments of the wildtype HDGF-allele (4, 386 bp) and the Tyr-HDGFgene construct (2, 570 bp).
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Page 5 of 12Figure 2 Detection of melanocyte-specific HDGF-overexpression. A: Immunofluorescence of skin samples from wildtype, HDGF
Tyr, HDGF
Tyr/
HDGF
-/- and HDGF
-/- mice. Paraffin sections were stained with affinity-purified anti-mouse HDGF antibody. Bound antibody was detected by
incubation with Cy3 conjugated secondary anti-rabbit antibody. Nuclei were stained with DAPI. a-e HDGF; f-j merge of HDGF, DAPI and
transmitted light. Green arrows point at HDGF positive melanocyte nuclei. Scale bar equates 100 μm. B: Primary melanocyte cell culture.
Melanocytes were isolated from newborn HDGF
Tyr, wildtype and HDGF
-/- mice. After 2-3 weeks melanocytes from wildtype and HDGF
-/- mice
grew in a sub-confluent cell layer, whereas very few melanocytes from HDGF
Tyr animals (red arrows) were able to survive in cell culture. a-c 100
× magnification; d-f 400 × magnification. Scale bar equates 100 μm. C: Western blot analysis of melanocyte lysates. a HDGF-level of primary
melanocytes from HDGF
Tyr, wildtype and HDGF
-/- mice was compared to the level of complete skin and B16F10 (murine melanoma cell line)
lysates. 10 μg total protein was loaded onto an SDS-gel. b Equal loading of melanocyte lysate was assessed by staining the membrane with
Coomassie solution.
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-/- mice (kindly provided by
Clemens Schmitt (Charité - University of Berlin) with
permission of Manuel Serrano [29]). These mice are
cancer prone and develop lymphoma and sarcoma spon-
taneously. Although the Ink4a gene locus is mutated in
about 40% of familiar melanoma, Ink4a
-/- mice do not
develop melanoma spontaneously [29]. But the introduc-
tion of an oncogene under the control of a melanocyte-
specific promoter like e.g. Tyr-HRas
(G12V) [37] or Tyr-
Tag [38] results in melanoma development. The ema-
nated HDGF
Tyr/Ink4a
-/-, Ink4a
-/- and HDGF
-/-/Ink4a
-/-
mice were monitored over their reduced life span (5-12
month) and analyzed histologically. Again, the mice
were viable, fertile, and showed no altered pigmentation
pattern nor did they turn gray prematurely. In addition,
no histological alterations concerning melanocyte num-
ber or location were observed. Therefore, HDGF
Tyr/
Ink4a
+/-, Ink4a
+/-, HDGF
-/-/Ink4a
+/-, as well as HDGF
Tyr,
wildtype, and HDGF
-/- mice were exposed to an addi-
tional mutagenic noxa. For this purpose, mice were neo-
natally exposed to a single UVB dose of 6.14 kJ/m
2
[39,40]. The 1-3 day old mice developed UV-erythema
resulting in peeling off the skin after 6-8 days. After
eight month animals of the genotypes HDGF
Tyr/Ink4a
+/-, Ink4a
+/-,H D G F
-/-/Ink4a
+/- developed pigmented
skin abnormalities (PSA) on tail and back skin, whereas
no abnormalities could be observed in HDGF
Tyr,w i l d -
type, and HDGF
-/- mice of up to 12 month after treat-
ment. The PSA of each HDGF
Tyr/Ink4a
+/-, Ink4a
+/-,o r
HDGF
-/-/Ink4a
+/- mouse were counted, sizes were
assessed and statistically evaluated (Figure 3B and 3C),
before they were subjected for histological analysis. Fig-
u r e3 As h o w se x e m p l a r yv i e w so ft h ei n n e rs i d eo ft h e
skin of HDGF
Tyr/Ink4a
+/-, Ink4a
+/-,a n dH D G F
-/-/Ink4a
+/- mice, exposing the highly pigmented lump. The
graph shows that HDGF
Tyr/Ink4a
+/- and Ink4a
+/- mice
developed comparable numbers and sizes of PSA,
whereas HDGF
-/-/Ink4a
+/- mice developed both more
and larger PSA. These findings were further analyzed by
applying a chi-square test to assess if the observed dis-
crepancy was statistically significant (Figure 3C).
Accordingly, HDGF
-/-/Ink4a
+/- mice developed signifi-
cantly more and larger PSA compared to both Ink4a
+/-
and HDGF
Tyr /Ink4a
+/- mice (p <0 . 0 0 1 ) .I nc o n t r a s t ,
t h es l i g h tt e n d e n c yo fI n k 4 a
+/- mice to develop more
PSA compared to HDGF
Tyr /Ink4a
+/- mice was not sta-
tistical significant.
For histological analysis serial sections were HE
stained or bleached before HE staining was performed
to examine the pigmented areas in detail (Figure 4A). In
addition, immunofluorescent staining was performed to
asses HDGF-expression in PSA (Figure 4B). HE-stain-
ings revealed that PSA did not resemble melanoma or
melanocytic lesions, but rather represent pigmented
epidermoid cysts, consisting of a lumen filled with kera-
tinized material surrounded by an epithelial layer of ker-
atinocytes. When comparing the bleached to the non-
bleached HE stained sections, it can be noticed that
there are only pigmented keratin fibres in the lumen,
but no viable cells (yellow arrows Figure 4A). Melano-
cytes are only located next to the keratinocyte layer
(green arrows Figure 4A).
Immunofluorescent staining revealed that both mela-
nocytes and keratinocytes of the epidermoid cysts
express HDGF (green arrows Figure 4B a, b, d, e). As
expected, no HDGF-expression could be detected in epi-
dermoid cysts derived from HDGF
-/-/Ink4a
+/- mice.
Notably, epidermoid cyst associated melanocytes from
wildtype animals showed a strong HDGF staining (Fig-
ure 4B b), whereas melanocytes in healthy, untreated
wildtype hair follicles express HDGF just to a very low
extend (Figure 2A a).
In summary, neither melanocyte targeted HDGF-over-
expression alone, nor in combination with a second
genetic alteration and/or UVB-treatment, led to the
development of melanocytic hyperplasia, or lesions in
which differences in melanocyte number between the
analyzed genotypes could be observed. Interestingly, not
HDGF overexpression but HDGF-deficiency led to the
development of an increased number and size of epider-
moid cysts after UVB-treatment.
Discussion
HDGF was shown to be overexpressed in several types
of tumors, like e.g. hepatocellular carcinoma [17,18] or
melanoma [23]. The correlation between the degree of
HDGF overexpression, disease prognosis
[16,18,20-22,24] and the role for HDGF in tumor angio-
genesis [25,26], metastasis [19,26], and apoptosis [27,28]
suggested that HDGF may function as an oncogene/pro-
tooncogene. In this study, a mouse model was generated
to address the question whether HDGF-overexpression
mediates oncogenic/transforming capacity to non-trans-
formed cells in vivo. We chose to target the HDGF
expression to melanocytes with the help of a Tyrosinase
promoter/enhancer element ( F i g u r e1 A )s i n c er e s u l t s
presented by Bernard and co-workers revealed HDGF-
expression in melanomas whereas HDGF was absent or
weakly present in nontumorigenetic melanocytes [23].
In addition, HDGF-expression was graded with progres-
sion, suggesting that the frequency of HDGF-expression
increases from benign nevi gradually to late melanoma
s t a g e s[ 2 3 ] .T h e r e f o r e ,i fH D G Fe x h i b i t so n c o g e n i c /
transforming capacity on melanocytes, loss or overex-
pression of HDGF are expected to have an influence on
tumor development and/or progression.
Transgene induced HDGF overexpression in melano-
cytes could be confirmed by comparing melanocytes
Sedlmaier et al. BMC Cancer 2011, 11:457
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Page 7 of 12Figure 3 Statistical analysis of pigmented skin abnormalities (PSA). A: Overview of the inner side of skins from HDGF
Tyr/Ink4a
+/-,I n k 4 a
+/-,
and HDGF
-/-/Ink4a
+/- mice showing PSA. Scale bar equates 1 cm. B: Statistical analysis of the occurrence of (PSA) of the different genotypes.
HDGF
Tyr/Ink4a
+/- n = 23, Ink4a
+/- n = 24; HDGF
-/-/Ink4a
+/- n = 23. C: Chi-square contingency table was applied for the category: largest PSA was
≤ 1mm or > 1mm. Contingency tables were carried out for the following pairs of genotypes: HDGF
Tyr/Ink4a
+/- - HDGF
-/-/Ink4a
+/- and Ink4a
+/- -
HDGF
-/-/Ink4a
+/-. Analysis was regarded significant for p < 0.01.
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Page 8 of 12Figure 4 Histological analysis of pigmented skin abnormalities (PSA). A: Serial sections of PSA were either directly HE stained (a-c) or
bleached in a benzylalcohol/aceton/H2O2 based bleaching solution before HE-staining was performed (d-f). Yellow arrows point to the
pigmented and to the bleached areas respectively within the cyst lumen; green arrows point to pigmented and bleached melanocytes
respectively. B: Immunofluorescence of epidermoid cysts. HDGF was detected by incubation with anti-mouse HDGF antibody and Cy3-
conjugated goat-anti-rabbit antibody (a-f). Nuclei were stained with DAPI. a-c HDGF; d-f merge of HDGF, DAPI and transmitted light. Green
arrows point to HDGF-positive nuclei in pigmented areas. Scale bars equate 100 μm.
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Page 9 of 12and tissues of wildtype and HDGF
Tyr/HDGF
-/- mice
(Figure 2, Additional file 1). No alterations regarding
melanocyte number and localization could be observed
in vivo in HDGF
Tyr, wildtype and HDGF
-/- mice, which
were additionally analyzed to investigate whether the
HDGF-deficiency has an impact on melanocytes in the
further conducted experiments. To favor the develop-
ment of tumors we introduced a second genetic altera-
tion and applied an additional mutagenic noxa. This was
done by deleting one copy of the Ink4a tumor suppres-
sor gene and exposure to mutagenic doses of UV-light.
Neonatal sunburn of HDGF
Tyr/Ink4a
+/-, Ink4a
+/-,a n d
HDGF
-/-/Ink4a
+/- mice led to the development of pig-
mented skin abnormalities (Figure 3). These abnormal-
ities, however, did not resemble melanocytic lesions, but
strongly resembled human epidermoid cysts. These cysts
are benign, round or oval in shape, are in contact with
the skin surface via a pore, and are confined by a squa-
mous epithelium which, through cornification, produces
a perl of keratinized material [41]. Epidermoid cysts
arise most frequently from the infundibulum of hair fol-
licles and represent a keratinocyte differentiation defect.
Pigmentation of epidermaoid cysts follows a definite
anatomic pattern and is dependent in humans on the
natural skin color [42,43]. No differences regarding pig-
mentation of murine epidermoid cysts of HDGF
Tyr/
Ink4a
+/-,I n k 4 a
+/-,o rH D G F
-/-/Ink4a
+/- mice could be
observed. Therefore, melanocytes located at the squa-
mous epithelium of epidermoid cysts seem to derive
from follicular melanocytes and the observed increased
number of melanocytes may be due to growth factors
released from cells of the benign cysts. Detailed analysis
of size and number of epidermoid cyst per animal
revealed a difference between the genotypes. Thus,
HDGF
-/-/Ink4a
+/- mice developed significantly more and
larger epidermoid cysts compared to both HDGF
Tyr/
Ink4a
+/- and Ink4a
+/- mice (Figure 3A-C). Morphologi-
cally keratinocytes of the outer root sheat (ORS) resem-
ble keratinocytes of the basal cell layer with which they
form a continuous cell layer. The morphology of epider-
moid cysts indicate that ORS keratinocytes run through
the differentiation program of epidermal keratinocytes
[44] resulting in the formation of a perl of keratinized
material. It is not clear why Ink4a
+/- mice develop epi-
dermoid cysts after a single neonatal UVB-treatment,
but our results show that additional HDGF-deficiency
leads to more and larger epidermoid cysts. The pre-
sented results therefore indicate that HDGF in wildtype
mice is involved in the control of keratinocyte differen-
tiation. So far, HDGF was reported to promote differen-
tiation of e.g. vascular smooth muscle cells [5,45,46]. In
addition, Enomoto and coworkers recently reported on
the investigation of an albumin-HDGF transgenic mouse
model targeting HDGF-overexpression to hepatocytes
[47]. In this case the overexpression of HDGF resulted
in delayed hepatocyte maturation, suggesting that
HDGF-overexpression in hepatocytes partially sup-
presses hepatocyte differentiation. In contrast, delayed
melanocyte maturation in HDGF
Tyr mice was not
obvious since skin and hair pigmentation of neonatal
HDGF
Tyr mice was indistinguishable from wildtype lit-
termates. The only hint on an impact of elevated
HDGF-levels on melanocyte differentiation came from
in vitro experiments. When we tried to culture primary
melanocytes from HDGF
Tyr, wildtype and HDGF
-/- new-
born mice, HDGF
Tyr melanocytes were not able to dif-
ferentiate and grow in a confluent pigmented cell layer
(Figure 2B).
In conclusion, the results obtained here implicate that
HDGF does not convey an oncogenic/transforming
capacity to melanocytes. In fact, our results and those
from other groups point to an involvement of HDGF in
cell differentiation. Nevertheless, the overexpression of
HDGF in various tumors and its validity as a prognostic
marker in some tumors points to a significant role of
this growth factor. Over the last years, the concept of
non-oncogene addiction (NOA) was established. This
concept describes the fact that tumors depend on the
expression or overexpression of several proteins, which
are not oncogenes, but which are secondarily regulated
and thus promote tumor progression [48]. These pro-
teins, like e.g. Stat5 or HSF1, help tumor cells to over-
come cellular stress which in normal cells would lead to
apoptosis [49,50]. In case of HSF1-deprivation tumor
cells die and tumors regress whereas normal cells do
not depend on this protein [51]. The latter certainly
applies for HDGF as shown by the normal development
and health of HDGF
-/- mice [15]. On the other hand, in
vitro and in vivo experiments showed that a reduction
of HDGF in transformed cells or the injection of HDGF
specific antibodies resulted in slowed tumor growth,
reduced number of blood vessels, and increased rate of
apoptosis [25,52-54]. These results and the results of
this study strongly suggest that HDGF does not possess
oncogenic/transforming capacities. Instead our results
and the results from other groups made us realize that
HDGF exhibits many criteria to fit into the concept of
non-oncogene addiction. This recommends HDGF as a
potential drug target with relevance for a variety of
tumors.
Conclusions
In summary, we developed an animal model overexpres-
sing HDGF in melanocytes. Our results provide no evi-
d e n c et h a tH D G Fh a sad i r e c tt r a n s f o r m i n gr o l ei n
tumor development. Instead, the here presented results
in combination with previous findings point to a possi-
ble role of the growth factor in cell differentiation and
Sedlmaier et al. BMC Cancer 2011, 11:457
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Page 10 of 12suggest that HDGF promotes tumor progression after
secondary upregulation. Therefore, HDGF may repre-
sent another protein fitting into the concept of non-
oncogene addiction of tumor tissue, supporting the
assumption of other research groups that HDGF could
serve as a target for cancer drug development.
Additional material
Additional file 1: Expressional analysis of the Tyrosinase-
HDGFgeneConstruct. A: Expression of the HDGFgene construct. Lysates
of HEK cells transfected with HDGFcdspCDNA3, HDGFgenepBEH or Mock
(pBEH) were separated by SDS-gel electrophoresis. HDGF protein
expression could be detected in samples transfected with
HDGFcdspCDNA3 and HDGFgenepBEH. B: Western blot analysis of brain
lysates. Brain lysates from wildtype, HDGF
Tyr, HDGF
-/- and HDGF
Tyr/
HDGF
-/- mice were analysed. HDGF could be detected in wildtype,
HDGF
Tyr and HDGF
Tyr/HDGF
-/- (white arrow) brain lysates. C: Detection of
HDGF-mRNA in mouse tissue. Total HDGF-mRNA was detected by
performing RT-PCR on cDNA from wildtype and HDGF
Tyr tissues using
primers spanning the complete HDGF coding sequence (HDGF-sense/
HDGF-antisense). The amplificated HDGF-mRNA could be detected as a
841 bp fragment in all samples (lane 1, 3, 5, 7, 9, and 11). Tyr-HDGF-
mRNA expressed from the Tyrosinase-HDGFgene construct could only be
detected in samples from the transgenic animal (red arrows; 861 bp
fragment in lane 4, 8, and 12).
Additional file 2: In Situ Hybridisation (ISH) and hematoxylin/eosin
(HE) staining of skin samples from HDGF
Tyr/HDGF
-/-, HDGF
-/-, and
wildtype mice. Paraffin sections were used to detect tyrosinase mRNA in
melanocytes by incubating the sections with the digoxygenin labeled
tyrosinase-antisense (Tyr as) probe or the tyrosinase-sense (Tyr s) probe
as a control. Bound probe was detected by incubation with alkaline
phosphatase coupled anti-digoxygenin Fab fragment. BM Purple was
used as a substrate. a-c HE-staining; d-f ISH Tyr_as; g-i ISH Tyr_s. Scale
bar equates 100 μm.
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